Corrections.
Where this comes from
- Record sourced from PubMed, PMID 26122440.
- Also identified by DOI 10.1016/S1473-3099(15)00111-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bourlière M, Bronowicki J-P, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397–404—In the second paragraph of the Randomisation and Masking section the sentence describing study drug assignment should have read: “Patients were assigned in a 1:1 ratio. In the ledipasvir-sofosbuvir plus ribavirin group..." [see text]